<![CDATA[Weighing Bispecific Antibodies Against CAR T-Cell Therapy in Follicular Lymphoma]]>

Summary

Dr. Nikesh Shah discussed clinical considerations for choosing between bispecific antibodies and CAR T-cell therapy in follicular lymphoma treatment. This is an educational commentary comparing treatment modalities with no new clinical data or regulatory announcements.